Stock ABVX ABIVAX
Add to a list
To use this feature you must be a member
Log inSign up

News Abivax

Equities

ABVX

FR0012333284

Market Closed - Euronext Paris
Other stock markets
 11:35:05 2024-07-12 am EDT 		5-day change 1st Jan Change
12.7 EUR +1.28% Intraday chart for Abivax +1.93% +29.33%
May. 20 BTIG Initiates Abivax at Buy Rating With $43 Price Target MT
May. 08 Abivax: four abstracts to be presented on obefazimod CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Abivax : Breakdown of the vote by resolution
PU
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
AQ
BTIG Initiates Abivax at Buy Rating With $43 Price Target
MT
Abivax: four abstracts to be presented on obefazimod
CF
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
EQ
Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024
CI
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
EQ
Abivax: share price rises as two analysts express optimism
CF
Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target
MT
Guggenheim Starts Abivax With Buy Rating, $50 Price Target
MT
Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating
MT
Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
AQ
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQ
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Abivax reports 2023 financial results and operational update
EQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO)
AQ
Abivax: presentation on obefazimod at the ECCO congress
CF
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQ
ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABVX Stock
  4. News Abivax